Company News

Cosperpharm supplies key intermediates for the synthesis of conivaptan hydrochloride, a dual vasopressin V₁ₐ/V₂ receptor antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Our portfolio focuses on the two critical building blocks required for the final assembly of the conivaptan molecule.

Cosperpharm supplies a focused portfolio of key intermediates for the synthesis of tolvaptan, an orally active nonpeptide arginine vasopressin V2 receptor antagonist used in the treatment of hyponatremia and autosomal dominant polycystic kidney disease. Our range covers critical building blocks along established synthetic routes, from the core benzazepine scaffold to advanced N-acyl intermediates.

Cosperpharm supplies a focused portfolio of key intermediates for the synthesis of midazolam, a short-acting benzodiazepine used in anesthesia, sedation, and seizure management. Our range covers critical building blocks and advanced intermediates along established synthetic routes.

Darolutamide (CAS 1297538-32-9), chemically designated as N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl]-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide, is a nonsteroidal androgen receptor (AR) antagonist developed by Bayer and Orion Corporation for the treatment of prostate cancer.

Cosperpharm supplies a comprehensive range of aromatic rings and aromatic heterocyclic systems for pharmaceutical, agrochemical, and fine chemical applications.

Cosperpharm supplies a broad portfolio of long-chain alkyl alcohols and ketones for pharmaceutical, cosmetic, and industrial applications. Our range covers saturated and unsaturated fatty alcohols.